{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:26:43Z","timestamp":1769088403562,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003748","name":"Svenska S\u00e4llskapet f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rituximab monotherapy is widely used for follicular lymphoma. However, there are no established predictors for response or response duration. We analyzed the long-term prognostic relevance of pre-treatment absolute blood counts of lymphocytes with subsets and monocytes in 265 follicular lymphoma patients, uniformly treated with rituximab without chemotherapy, in two Nordic Lymphoma Group trials. There were 265 previously untreated, stage II\u2013IV follicular lymphoma patients with a median follow-up of over 10\u00a0years. Absolute B cell counts \u2265 median (0.09\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L) were an independent predictor for shorter time to next treatment or death (multivariable analysis <jats:italic>P<\/jats:italic>\u2009=\u20090.010). In univariate analysis, absolute monocyte counts \u2265 median (0.5\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L) did not correlate with time to next treatment or death, but with inferior overall survival (<jats:italic>P<\/jats:italic>\u2009=\u20090.034). Absolute T cell or T cell subset counts were not predictive for outcome. High absolute B cell counts, possibly reflecting circulating lymphoma cells, have an unfavorable impact on time to next treatment or death in patients treated with rituximab without chemotherapy.<\/jats:p>","DOI":"10.1007\/s00277-020-04208-x","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T22:03:05Z","timestamp":1597701785000},"page":"2357-2366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy"],"prefix":"10.1007","volume":"99","author":[{"given":"Henna-Riikka","family":"Junl\u00e9n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Lockmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3566-8847","authenticated-orcid":false,"given":"Bj\u00f6rn Engelbrekt","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,17]]},"reference":[{"key":"4208_CR1","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon"},{"issue":"5","key":"4208_CR2","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hageenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular Lymphoma International Prognostic Index. Blood 104(5):1258\u20131265. https:\/\/doi.org\/10.1182\/blood-2003-12-4434","journal-title":"Blood"},{"issue":"5","key":"4208_CR3","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","volume":"108","author":"C Buske","year":"2006","unstructured":"Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W (2006) The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108(5):1504\u20131508","journal-title":"Blood"},{"issue":"1","key":"4208_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.56.1","volume":"56","author":"T Sugimoto","year":"2016","unstructured":"Sugimoto T, Watanabe T (2016) Follicular lymphoma: the role of the tumor microenvironment in prognosis. J Clin Exp Hematop 56(1):1\u201319. https:\/\/doi.org\/10.3960\/jslrt.56.1","journal-title":"J Clin Exp Hematop"},{"issue":"12","key":"4208_CR5","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-11-0264","volume":"17","author":"BE Wahlin","year":"2011","unstructured":"Wahlin BE, Sundstrom C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Linden O, Nordstrom M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenholder M, Tierens AM, Sander B, Christensson B, Kimby E (2011) T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. Clin Cancer Res 17(12):4136\u20134144. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0264","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4208_CR6","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","volume":"104","author":"G Cartron","year":"2004","unstructured":"Cartron G, Watier H, Golay J, Solal-Celigny P (2004) From the bench to the bedside: ways to improve rituximab efficacy. Blood 104(9):2635\u20132642","journal-title":"Blood"},{"issue":"4","key":"4208_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/10428194.2011.637211","volume":"53","author":"RA Wilcox","year":"2012","unstructured":"Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L (2012) The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma 53(4):575\u2013580. https:\/\/doi.org\/10.3109\/10428194.2011.637211","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4208_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3324\/haematol.2013.088161","volume":"99","author":"T Tadmor","year":"2014","unstructured":"Tadmor T, Bari A, Sacchi S, Marcheselli L, Liardo EV, Avivi I, Benyamini N, Attias D, Pozzi S, Cox MC, Baldini L, Brugiatelli M, Federico M, Polliack A (2014) Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica 99(1):125\u2013130. https:\/\/doi.org\/10.3324\/haematol.2013.088161","journal-title":"Haematologica"},{"issue":"4","key":"4208_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bjh.12409","volume":"162","author":"KA von Hohenstaufen","year":"2013","unstructured":"von Hohenstaufen KA, Conconi A, de Campos CP, Franceschetti S, Bertoni F, Margiotta Casaluci G, Stathis A, Ghielmini M, Stussi G, Cavalli F, Gaidano G, Zucca E (2013) Prognostic impact of monocyte count at presentation in mantle cell lymphoma. Br J Haematol 162(4):465\u2013473. https:\/\/doi.org\/10.1111\/bjh.12409","journal-title":"Br J Haematol"},{"key":"4208_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.leukres.2015.12.010","volume":"42","author":"YQ Yang","year":"2016","unstructured":"Yang YQ, Liang JH, Wu JZ, Wang L, Qu XY, Cao L, Zhao XL, Huang DP, Fan L, Li JY, Xu W (2016) Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma. Leuk Res 42:88\u201392. https:\/\/doi.org\/10.1016\/j.leukres.2015.12.010","journal-title":"Leuk Res"},{"key":"4208_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/1471-2407-13-222","volume":"13","author":"JJ Huang","year":"2013","unstructured":"Huang JJ, Li YJ, Xia Y, Wang Y, Wei WX, Zhu YJ, Lin TY, Huang HQ, Jiang WQ, Li ZM (2013) Prognostic significance of peripheral monocyte count in patients with extranodal natural killer\/T-cell lymphoma. BMC Cancer 13:222. https:\/\/doi.org\/10.1186\/1471-2407-13-222","journal-title":"BMC Cancer"},{"issue":"6","key":"4208_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","volume":"134","author":"M Siddiqui","year":"2006","unstructured":"Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Call TG, Porrata LF (2006) Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 134(6):596\u2013601","journal-title":"Br J Haematol"},{"issue":"5","key":"4208_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2141.2007.06596.x","volume":"137","author":"D Behl","year":"2007","unstructured":"Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Porrata LF (2007) Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 137(5):409\u2013415. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06596.x","journal-title":"Br J Haematol"},{"issue":"10","key":"4208_CR14","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Rufibach K, Salles G, Leoncini-Franscini L, Leger-Falandry C, Cogliatti S, Fey M, Martinelli G, Stahel R, Lohri A, Ketterer N, Wernli M, Cerny T, Schmitz SF (2005) Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16(10):1675\u20131682","journal-title":"Ann Oncol"},{"issue":"21","key":"4208_CR15","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/nejm199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N Engl J Med 339(21):1506\u20131514. https:\/\/doi.org\/10.1056\/nejm199811193392104","journal-title":"N Engl J Med"},{"issue":"10","key":"4208_CR16","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/sj.leu.2404780","volume":"21","author":"DH Kim","year":"2007","unstructured":"Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, Song HS, Chung JS, Hyun MS, Sohn SK (2007) Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 21(10):2227\u20132230. https:\/\/doi.org\/10.1038\/sj.leu.2404780","journal-title":"Leukemia"},{"issue":"10","key":"4208_CR17","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3109\/10428194.2010.508189","volume":"51","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Morales D, Quinones P, Cotrina E, Desposorio C, Beltran B (2010) Lymphopenia as a prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma 51(10):1822\u20131828. https:\/\/doi.org\/10.3109\/10428194.2010.508189","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"4208_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.23205","volume":"87","author":"Z Mitrovic","year":"2012","unstructured":"Mitrovic Z, Perry AM, Suzumiya J, Armitage JO, Au WY, Coiffier B, Holte H, Jaffe ES, Monserrat E, Rajan SK, Savage KJ, Tobinai K, Vose JM, Weisenburger DD (2012) The prognostic significance of lymphopenia in peripheral T-cell and natural killer\/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma Project. Am J Hematol 87(8):790\u2013794. https:\/\/doi.org\/10.1002\/ajh.23205","journal-title":"Am J Hematol"},{"issue":"2","key":"4208_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/10428194.2013.802778","volume":"55","author":"BE Wahlin","year":"2014","unstructured":"Wahlin BE, Sundstrom C, Sander B, Christensson B, Jeppsson-Ahlberg A, Hjalmarsson E, Holte H, Ostenstad B, Brown PD, Smeland EB, Kimby E (2014) Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk Lymphoma 55(2):288\u2013295. https:\/\/doi.org\/10.3109\/10428194.2013.802778","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"4208_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/10428190701704647","volume":"49","author":"E Kimby","year":"2008","unstructured":"Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T, Ostenstad B, Hansen M, Osterborg A, Linden O, Sundstrom C (2008) Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 49(1):102\u2013112. https:\/\/doi.org\/10.1080\/10428190701704647","journal-title":"Leuk Lymphoma"},{"key":"4208_CR21","doi-asserted-by":"publisher","unstructured":"Kimby E, Ostenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundstrom C (2015) Two courses of four weekly infusions of rituximab with or without interferon-alpha2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. Leuk Lymphoma 1\u201310. https:\/\/doi.org\/10.3109\/10428194.2015.1014363","DOI":"10.3109\/10428194.2015.1014363"},{"key":"4208_CR22","doi-asserted-by":"publisher","unstructured":"Lockmer S, Ostenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenholder M, Smedby KE, Brown P, Kimby E (2018) Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two Nordic Lymphoma Group trials with more than 10 years of follow-up. J Clin Oncol JCO1800262. https:\/\/doi.org\/10.1200\/JCO.18.00262","DOI":"10.1200\/JCO.18.00262"},{"key":"4208_CR23","first-page":"682","volume-title":"Hematology, basic principles and practice","author":"MP Mims","year":"2018","unstructured":"Mims MP (2018) Lymphocytosis, lymphocytopenia, hypergammaglobulinemia, and hypogammaglobulinemia. In: EJB RH Jr, Silberstein LE, Heslop H, Weitz J, Anastasi J (eds) Hematology, basic principles and practice, 7th edn. Churchill Livingstone\/Elsevier, Philadelphia, pp 682\u2013690","edition":"7"},{"issue":"10","key":"4208_CR24","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.leukres.2013.07.015","volume":"37","author":"R Watanabe","year":"2013","unstructured":"Watanabe R, Tomita N, Kishimoto K, Koyama S, Ogusa E, Ishii Y, Miyashita K, Matsuura S, Fujisawa S, Hattori Y, Takasaki H, Fujita A, Ohshima R, Kuwabara H, Hashimoto C, Fujimaki K, Sakai R, Ishigatsubo Y (2013) Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Res 37(10):1208\u20131212. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.015","journal-title":"Leuk Res"},{"issue":"4","key":"4208_CR25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/bjh.13332","volume":"169","author":"L Marcheselli","year":"2015","unstructured":"Marcheselli L, Bari A, Anastasia A, Botto B, Puccini B, Dondi A, Carella AM, Alvarez I, Chiarenza A, Arcari A, Salvi F, Federico M (2015) Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Br J Haematol 169(4):544\u2013551. https:\/\/doi.org\/10.1111\/bjh.13332","journal-title":"Br J Haematol"},{"issue":"9","key":"4208_CR26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.leukres.2013.05.016","volume":"37","author":"BE Beltran","year":"2013","unstructured":"Beltran BE, Qui\u00f1ones P, Morales D, Alva JC, Miranda RN, Lu G, Shah BD, Sotomayor EM, Castillo JJ (2013) Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res 37(9):1116\u20131119. https:\/\/doi.org\/10.1016\/j.leukres.2013.05.016","journal-title":"Leuk Res"},{"issue":"7","key":"4208_CR27","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.3109\/10428194.2014.963578","volume":"56","author":"AM Maeshima","year":"2015","unstructured":"Maeshima AM, Taniguchi H, Tanioka K, Kitahara H, Miyamoto K, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kobayashi Y, Tobinai K, Kushima R (2015) Clinicopathological characteristics of follicular lymphoma with peripheral blood involvement. Leuk Lymphoma 56(7):2000\u20132004. https:\/\/doi.org\/10.3109\/10428194.2014.963578","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4208_CR28","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bjh.12675","volume":"164","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy C, Baseggio L, Feugier P, Callet-Bauchu E, Karlin L, Seymour JF, Lebras L, Michallet AS, Offner F, Dumas O, Traverse-Glehen A, Ffrench M, Lopez-Guillermo A, Berger F, Coiffier B, Felman P, Salles G (2014) Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. Br J Haematol 164(5):659\u2013667. https:\/\/doi.org\/10.1111\/bjh.12675","journal-title":"Br J Haematol"},{"key":"4208_CR29","doi-asserted-by":"crossref","unstructured":"Kodaira M, Takeuchi K, Nara E, Nakano K, Ueda K, Yamada S, Mishima Y, Yokoyama M, Terui Y, Hatake K (2009) Leukemic presentation is predictive indicator for relapse for patients with follicular lymphoma treated with rituximab containing initial therapy. Paper presented at the ASH Annual Meeting Abstracts, Dec 05\u201308","DOI":"10.1182\/blood.V114.22.4763.4763"},{"issue":"17","key":"4208_CR30","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood-2014-02-553693","volume":"123","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy C, Seymour JF, Ferme C, Caballero D, Ghesquieres H, Leppa S, Delarue R, Pedersen LM, Mounier C, Gomes Da Silva M, Chassagne-Clement C, Maerevoet M, Salles G (2014) Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma. Blood 123(17):2740\u20132742. https:\/\/doi.org\/10.1182\/blood-2014-02-553693","journal-title":"Blood"},{"issue":"9","key":"4208_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D (1998) Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol 9(9):995\u20131001","journal-title":"Ann Oncol"},{"issue":"9","key":"4208_CR32","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3324\/haematol.2011.059246","volume":"97","author":"U Jager","year":"2012","unstructured":"Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, Mannhalter C, Oberaigner W, Porpaczy E, Skrabs C, Einberger C, Drach J, Raderer M, Gaiger A, Putman M, Greil R, Arbeitsgemeinschaft Medikamentose Tumortherapie I (2012) Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97(9):1431\u20131438. https:\/\/doi.org\/10.3324\/haematol.2011.059246","journal-title":"Haematologica"},{"issue":"23","key":"4208_CR33","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.1158\/1078-0432.ccr-13-1120","volume":"19","author":"OW Press","year":"2013","unstructured":"Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI (2013) A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res 19(23):6624\u20136632. https:\/\/doi.org\/10.1158\/1078-0432.ccr-13-1120","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4208_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","volume":"132","author":"E Bachy","year":"2018","unstructured":"Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132(1):49\u201358. https:\/\/doi.org\/10.1182\/blood-2017-11-816405","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04208-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04208-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T23:30:00Z","timestamp":1629156600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04208-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,17]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["4208"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04208-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,17]]},"assertion":[{"value":"4 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in the trials were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants enrolled in the trials. Clinical follow-up data was obtained from an ethically approved, recently published follow-up study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BEW has been a consultant for Roche. EK has previously got research funds from Roche, but not for this project. H-RJ and SL declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}